Subcutaneous alemtuzumab (MabCampath) in fludarabine-refractory CLL (CLL2H trial of the GCLLSG)

被引：11
|
作者：
Stilgenbauer, Stephan [1 ]
Winkler, Dirk [1 ]
Buehler, Andreas [1 ]
Zenz, Thorsten [1 ]
Groner, Sija [1 ]
Busch, Raymonde [1 ]
Hensel, Manfred [1 ]
Duehrsen, Uhich [1 ]
Finke, Juergen [1 ]
Dreger, Peter [1 ]
Jaeger, Ulrich [1 ]
Lengfelder, Eva [1 ]
Truemper, Lorenz [1 ]
Soeling, Ulrike [1 ]
Schlag, Rudolf [1 ]
Hallek, Michael [1 ]
Doehner, Hartmut [1 ]
机构：
[1] Univ Ulm, D-89069 Ulm, Germany
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.3120.3120
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3120
引用
收藏
页码：918A / 918A
页数：1
相关论文
共 50 条
  • [41] Bendamustine, followed by obinutuzumab, acalabrutinib and venetoclax in patients (Pts) with relapsed/refractory chronic lymphocytic Leukemia (CLL): updated results of the CLL2-BAAG trial of the German CLL Study Group (GCLLSG)
    Cramer, Paula
    Fuerstenau, Moritz
    Robrecht, Sandra
    Giza, Adam
    Fink, Anna
    Fischer, Kirsten
    Langerbeins, Petra
    Al-Sawaf, Othman
    Tausch, Eugen
    Schneider, Christof
    Schetelig, Johannes
    Dreger, Peter
    Boettcher, Sebastian
    Kreuzer, Karl-Anton
    Schilhabel, Anke
    Brueggemann, Monika
    Kneba, Michael
    Wendtner, Clemens
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Hallek, Michael
    LEUKEMIA & LYMPHOMA, 2023, 64 : S18 - S19
  • [42] Report of the UKCLL02 trial: a phase II study of subcutaneous alemtuzumab and fluclarabine in patients with fluclarabine refractory CLL (on behalf of the NCRI CLL trials sub-group)
    Sayala, H. A.
    Moreton, P.
    Jones, R. A.
    Rawstron, A. C.
    O'Connor, S. J.
    Evans, P. E.
    Carter, A.
    Dearden, C.
    Matutes, E.
    Pettitt, A. R.
    Kennedy, B. D.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 : 3 - 3
  • [43] FINAL RESULTS OF ORAL FLUDARABINE WITH CONCOMITANT SUBCUTANEOUS ALEMTUZUMAB IN RELAPSED/REFRACTORY B-CHRONIC LYMPHOCYTIC LEUKAEMIA (B-CLL): THE FLUSALEM STUDY
    Egle, A.
    Melchardt, T.
    Pleyer, L.
    Tinhofer, I.
    Lang, A.
    Keil, F.
    Thaler, J.
    Gunsilius, E.
    Fridrik, M.
    Greil, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 140 - 140
  • [44] Bendamustine (B), followed by obinutuzumab (G) and venetoclax (A) in patients with chronic lymphocytic leukemia (CLL): CLL2-BAG trial of the German CLL Study Group (GCLLSG)
    Cramer, P.
    von Tresckow, J.
    Bahlo, J.
    Robrecht, S.
    Al-Sawaf, O.
    Langerbeins, P.
    Engelke, A.
    Fink, A. -M.
    Fischer, K.
    Tausch, E.
    Seiler, T.
    von Weikersthal, Fischer L.
    Hebart, H.
    Kreuzer, K. -A.
    Ritgen, M.
    Kneba, M.
    Wendtner, C. -M.
    Stilgenbauer, S.
    Eichhorst, B.
    Hallek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 24 - 24
  • [45] R-DHAP Is Effective in Fludarabine-Refractory CLL, Possibly Via Upregulation of Pro-Apoptotic P73.
    Tonino, Sanne H.
    Van Gelder, Michel
    Eldering, Eric
    van Oers, Marinus H. J.
    Kater, Arnon P.
    BLOOD, 2009, 114 (22) : 1340 - 1340
  • [46] Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab (FC-Cam) in Patients with Relapsed or Genetic High-Risk CLL: Final Analysis of the CLL2L Trial of the German CLL Study Group
    Elter, Thomas
    James, Rojin
    Stilgenbauer, Stephan
    Boettcher, Sebastian
    Ritgen, Matthias
    Doehner, Hartmut
    Hallek, Michael
    Engert, Andreas
    BLOOD, 2009, 114 (22) : 92 - 92
  • [47] CHOP plus rituximab (CHOP-R) in fludarabine (F) refractory chronic lymphocytic leukemia (CLL) or CLL with autoimmune hemolytic anemia (AIHA) or Richter's transformation (RT): First interim analysis of a phase II trial of the German CLL study group (GCLLSG).
    Eichhorst, BF
    Busch, R
    Duehrsen, U
    Schulz, H
    Wendtner, CM
    Goebeler, ME
    Hallek, M
    BLOOD, 2005, 106 (11) : 601A - 601A
  • [48] Outpatient-based therapy with oral fludarabine and alemtuzumab for Asian patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
    Hwang, William
    Dearden, C.
    Loh, S. M.
    Linn, Y. C.
    Tien, S. L.
    Teoh, G.
    Lim, L. F.
    Liew, P. X.
    How, G. F.
    Heng, K. K.
    Goh, Y. T.
    Lee, L. H.
    BLOOD, 2006, 108 (11) : 336B - 337B
  • [49] Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL study group (GCLLSG).
    Wendtner, CM
    Ritgen, M
    Schweighofer, CD
    Fingerle-Rowson, G
    Campe, H
    Jaeger, G
    Eichhorst, B
    Busch, R
    Diem, H
    Engert, A
    Stilgenbauer, S
    Doehner, H
    Kneba, M
    Emmerich, B
    Hallek, M
    BLOOD, 2003, 102 (11) : 676A - 676A
  • [50] Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
    C-M Wendtner
    M Ritgen
    C D Schweighofer
    G Fingerle-Rowson
    H Campe
    G Jäger
    B Eichhorst
    R Busch
    H Diem
    A Engert
    S Stilgenbauer
    H Döhner
    M Kneba
    B Emmerich
    M Hallek
    Leukemia, 2004, 18 : 1093 - 1101
12345